6.7
Adrenerjik Agonistler: Karma Etkili Ajanlar
Efedrin ve psödoefedrin gibi karışık etkili adrenerjik agonistler, adrenerjik reseptörleri doğrudan ve dolaylı olarak etkiler. Bu ajanlar, adrenoseptö…
Karışık etkili adrenerjik agonistler doğrudan adrenoseptörleri uyararak ve dolaylı olarak sinir terminallerinden depolanmış katekolaminleri serbest bırakarak etki ederler.
Endojen katekolaminlerin aksine, karışık etkili agonistler bir katekol parçasından yoksundur, bu da onları enzimleri metabolize etmek için zayıf substratlar haline getirir ve etki sürelerini arttırır.
Hem efedrin hem de psödoefedrin mükemmel oral biyoyararlanım ve CNS penetrasyonu sergiler, ancak katekolaminlerden daha az etkilidir.
Ephedra bitkisinden izole edilen efedrin, astımı tedavi etmek için oral olarak aktif bir sempatomimetik olarak kullanılmıştır.
Efedrin kardiyak stimülasyona ve vazokonstriksiyona neden olduğundan, anesteziye bağlı hipotansiyonu tedavi etmek için kullanılır. Bununla birlikte, izoprenaline veya adrenalinden daha az güçlü bir bronkodilatördür.
Ek olarak, merkezi uyarıcı etkileri, bir performans arttırıcı olarak kötüye kullanılmasından sorumludur.
Daha dolaylı etkiye sahip bir efedrin izomeri olan psödoefedrin oral olarak etkilidir ve daha az CNS etkisine sahiptir. Esas olarak bir dekonjestan olarak kullanılır.
Yasadışı metamfetamin üretiminde yaygın olarak öncü olarak kullanıldığından, satışı sıkı bir şekilde düzenlenmektedir.
View the full transcript and gain access to JoVE Core videos
Q1: How do mixed-acting adrenergic agonists differ from direct-acting agents?
Mixed-acting adrenergic agonists both stimulate adrenoceptors directly and indirectly release stored catecholamines from nerve terminals, amplifying the adrenergic response. Direct-acting agents only bind to receptors. Mixed-acting agents like ephedrine and pseudoephedrine lack a catechol moiety, making them resistant to metabolic degradation and extending their duration of action compared to endogenous catecholamines.
Q2: Why do ephedrine and pseudoephedrine have better oral bioavailability than catecholamines?
Ephedrine and pseudoephedrine lack a catechol moiety, which makes them poor substrates for metabolizing enzymes. This structural difference prevents rapid degradation, increasing their oral bioavailability and allowing them to reach systemic circulation effectively. Their lipophilicity also enhances absorption and CNS penetration, though they remain less potent than endogenous catecholamines.
Q3: What are the main clinical uses of ephedrine?
Ephedrine is used orally as a sympathomimetic agent for treating asthma and managing anesthesia-induced hypotension due to its cardiac stimulation and vasoconstriction effects. However, it is a less potent bronchodilator than isoprenaline or adrenaline. Its central stimulatory effects have led to abuse as a performance enhancer, limiting its therapeutic application.
Q4: Why is pseudoephedrine primarily used as a decongestant rather than for asthma?
Pseudoephedrine, an ephedrine isomer with predominantly indirect action, is orally effective with fewer central nervous system effects than ephedrine. These reduced CNS effects make it suitable for nasal decongestant use without significant stimulatory side effects. Its indirect mechanism of action and safety profile favor its use for congestion relief over asthma treatment.
Q5: How does prior catecholamine depletion affect mixed-acting agonist response?
Mixed-acting adrenergic agonists depend on releasing stored neurotransmitters for their indirect effects. Prior treatment with catecholamine-depleting agents like guanethidine or reserpine significantly reduces the agonist response by eliminating available stored catecholamines. This demonstrates the importance of the indirect mechanism in mixed-acting agent efficacy.
Q6: Why is pseudoephedrine's sale strictly regulated?
Pseudoephedrine is commonly used as a precursor in illegal methamphetamine production. Due to this abuse potential, its sale is strictly regulated to prevent diversion for illicit drug synthesis. Despite its legitimate therapeutic use as a decongestant, regulatory restrictions limit its availability and distribution.
Q7: What structural feature allows mixed-acting agonists to resist enzymatic degradation?
Mixed-acting adrenergic agonists like ephedrine and pseudoephedrine lack a catechol moiety present in endogenous catecholamines. This absence makes them poor substrates for metabolizing enzymes, preventing rapid degradation and increasing their duration of action. This structural modification is key to their extended therapeutic effect compared to natural catecholamines.